Also known as: B-cell cancers
Sana Biotechnology will present preclinical data for SG293, an in vivo CAR T candidate, at ASGCT 2026. The presentation covers a CD8-targeted fusosome that generates CD19-directed CAR T cells in NHPs.
The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.
ImmunoACT's domestically manufactured CAR-T therapy has treated over 600 patients with relapsed or refractory B-cell malignancies since its 2023 approval, marking India's entry into advanced cellular therapy production.
